BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO
Bio-Techne (NASDAQ: TECH) announced its participation in the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo from November 19-23 in Vancouver. Through its brand Asuragen, the company will showcase new research products for breast cancer monitoring and carrier screening at booth #811. The event features workshops on the QuantideX® qPCR ESR1 exoMutation Kit and AmplideX® Nanopore Carrier Plus Kit, along with discussions on LDT compliance. Multiple research posters will be presented covering topics including ESR1 mutations detection, complex variant genotyping, and molecular testing advances.
Bio-Techne (NASDAQ: TECH) ha annunciato la sua partecipazione all'Annual Meeting & Expo 2024 dell'Association for Molecular Pathology (AMP) che si svolgerà dal 19 al 23 novembre a Vancouver. Attraverso il suo marchio Asuragen, l'azienda presenterà nuovi prodotti di ricerca per il monitoraggio del cancro al seno e lo screening dei portatori allo stand #811. L'evento includerà workshop sul QuantideX® qPCR ESR1 exoMutation Kit e AmplideX® Nanopore Carrier Plus Kit, insieme a discussioni sulla conformità agli LDT. Saranno presentati diversi poster di ricerca che tratteranno argomenti come la rilevazione delle mutazioni ESR1, il genotipizzazione delle varianti complesse e i progressi nei test molecolari.
Bio-Techne (NASDAQ: TECH) anunció su participación en la Reunión Anual y Expo 2024 de la Asociación de Patología Molecular (AMP) que se llevará a cabo del 19 al 23 de noviembre en Vancouver. A través de su marca Asuragen, la empresa exhibirá nuevos productos de investigación para el monitoreo del cáncer de mama y la selección de portadores en el stand #811. El evento contará con talleres sobre el Kit QuantideX® qPCR ESR1 exoMutation y el Kit AmplideX® Nanopore Carrier Plus, junto con discusiones sobre el cumplimiento de LDT. Se presentarán múltiples carteles de investigación que cubrirán temas como la detección de mutaciones ESR1, el genotipado de variantes complejas y los avances en pruebas moleculares.
Bio-Techne (NASDAQ: TECH)는 2024년 11월 19일부터 23일까지 밴쿠버에서 열리는 분자 병리학 협회(AMP) 연례 회의 및 박람회에 참여한다고 발표했습니다. 회사는 Asuragen 브랜드를 통해 유방암 모니터링 및 보유자 스크리닝을 위한 새로운 연구 제품을 부스 #811에서 선보일 예정입니다. 이 이벤트는 QuantideX® qPCR ESR1 exoMutation 키트 및 AmplideX® Nanopore Carrier Plus 키트에 대한 워크숍과 LDT 준수에 대한 논의를 포함합니다. ESR1 돌연변이 탐지, 복합 변이 유전형 분석 및 분자 테스트 발전을 다루는 여러 연구 포스터가 발표될 것입니다.
Bio-Techne (NASDAQ: TECH) a annoncé sa participation à la réunion annuelle et à l'Expo 2024 de l'Association for Molecular Pathology (AMP) qui se tiendra du 19 au 23 novembre à Vancouver. À travers sa marque Asuragen, l'entreprise présentera de nouveaux produits de recherche pour le suivi du cancer du sein et le dépistage des porteurs au stand #811. L'événement comprendra des ateliers sur le kit QuantideX® qPCR ESR1 exoMutation et le kit AmplideX® Nanopore Carrier Plus, ainsi que des discussions sur la conformité aux LDT. Plusieurs posters de recherche seront présentés, traitant de sujets comme la détection des mutations ESR1, le génotypage de variants complexes et les avancées des tests moléculaires.
Bio-Techne (NASDAQ: TECH) hat seine Teilnahme an der jährlichen Tagung und Expo 2024 der Association for Molecular Pathology (AMP) angekündigt, die vom 19. bis 23. November in Vancouver stattfindet. Durch seine Marke Asuragen wird das Unternehmen neue Forschungsprodukte für das Monitoring von Brustkrebs und das Trägerscreening am Stand #811 präsentieren. Die Veranstaltung umfasst Workshops zum QuantideX® qPCR ESR1 exoMutation Kit und zum AmplideX® Nanopore Carrier Plus Kit sowie Diskussionen zur LDT-Konformität. Mehrere Forschungsposter werden präsentiert, die Themen wie die Erkennung von ESR1-Mutationen, komplexe Varianten-Genotypisierung und Fortschritte in der molekularen Diagnostik abdecken.
- Showcasing new diagnostic products for breast cancer monitoring and carrier screening
- QuantideX® qPCR ESR1 exoMutation Kit achieves high analytical sensitivity of ≤0.1% across 11 ESR1 mutations
- None.
Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees
"The Association for Molecular Pathology is a leading voice in the world of clinical molecular testing. We look forward to its meeting every year to discuss the latest advances in molecular diagnostics and how they can be deployed for improved laboratory outcomes," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "This year, we're excited to highlight important new products that will help labs streamline data collection and analysis in critical areas including metastatic breast cancer and carrier screening."
At the AMP 2024 Annual Meeting & Expo, Asuragen will host, sponsor, or participate in a number of activities and presentations.
ESR1 & Beyond: Leveraging Exosomes for Highly-Sensitive Variant Detection on qPCR
This workshop will showcase the design and performance of the QuantideX® qPCR ESR1 exoMutation Kit combined with the ExoLution Plus cfDNA + exoRNA Isolation Kit to achieve analytical sensitivity of ≤
Speaker: Brian Haynes, PhD, Bio-Techne Diagnostics Division
Date and time: Wednesday, November 20, 3:00-3:50 PM PST
Location: Room 212/213
Long-Range PCR Meets Long-Read Sequencing: An Assay for 11 Hard-to-Decipher, High-Frequency Carrier Screening Associated Genes
This workshop will focus on the design and performance of the AmplideX® Nanopore Carrier Plus Kit, combining AmplideX PCR chemistry with the Oxford Nanopore® platform to identify the most challenging genetic alterations like CNVs, large inversions, and pseudogenes using a consolidated workflow.
Speaker: Paul A. Wadsworth, MD, PhD, Resident Physician, Pathology, Stanford University
Date and time: Wednesday, November 20, 12:00-12:50 PM PST
Location: Room 114/115
Fireside Chat: LDT Compliance in an Uncertain Environment
With so much uncertainty around the FDA's laboratory-developed test (LDT) rule, it is challenging for laboratory leaders to make firm plans for how to achieve compliance. This session will consider three different tactical approaches for stage I of the rule: a) labs actively preparing for compliance; b) labs preparing, but cautiously using resources; and c) labs that are taking a 'wait and see' approach.
Discussion Leader: Jordan Laser, MD, Asuragen
Date and time: Wednesday, November 20, 5:15-6:15 PM PST
Location: Room 211
POSTERS
Verification of an RT-qPCR Assay System for Liquid Biopsy Surveillance of Treatment-Resistant ESR1 Mutations
Presenting author: Blaine Caughron, Asuragen
Poster info: G095, Genetics; Saturday, November 23, 9:15 am -10:15 am
Verification of an Amplification-Based Nanopore Sequencing Assay and Software to Genotype Complex, Clinically-Relevant Variants in 11 Hard-to-Decipher Genes with High Carrier Frequencies
Presenting author: Connor A. Parker, Asuragen
Poster info: G094, Genetics; Friday, November 22, 9:15 am -10:15 am
Freeze-Dried, Worry Thawed: Armored RNA New Lyophilized Controls Offer Potential to Advance Molecular Testing in Resource Limited Settings
Presenting author: Deepa Eveleigh, Asuragen
Poster info: ID046, Infectious Disease; Friday, November 22, 9:15 am -10:15 am
Beta Evaluation of a Panel of 11 Challenging Genes Using ONT/AmplideX Chemistry
Presenting author: Anne-Sophie Lebre, Professor of Human Genetics & Clinical Molecular Geneticist, Reims Medical School & University Hospital
Poster info: G013, Genetics; Saturday, November 23, 9:15am -10:15am
Stop by the Asuragen booth (#811) to learn more about the company's products for clinical laboratories. We will also be providing free, professional-quality headshots to all AMP attendees who visit our booth on Thursday or Friday.
For more information about Asuragen's AMP 2024 activities, please visit https://www.bio-techne.com/about/events/association-molecular-pathology.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
Contact:
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-highlight-novel-solutions-for-cancer-and-carrier-screening-at-amp-2024-annual-meeting--expo-302305212.html
SOURCE Bio-Techne Corporation
FAQ
What products will Bio-Techne (TECH) showcase at AMP 2024?
When and where is Bio-Techne (TECH) presenting at AMP 2024?